Type 1 diabetes (T1D) is a disease where the body's immune system attacks cells in the pancreas called β cells, which help control blood sugar. There are three stages of T1D:
- Stage 1: People have special proteins called islet autoantibodies in their blood, but no symptoms or blood sugar issues.
- Stage 2: These people also have islet autoantibodies and some blood sugar problems, but still no symptoms.
- Stage 3: People show symptoms and have high blood sugar levels, needing insulin treatment.
Teplizumab is a treatment that has shown to slow down reaching Stage 3 in people at Stage 2 in a study. This study collects information on people using teplizumab to see who it helps and how they are treated afterwards.
- Participants must agree to join and have been treated with teplizumab for at least one day.
- People in other ongoing clinical studies can't join.
- This is not an interventional trial, meaning no new treatments will be tested.
How understandable was the trial content above?
Hard to understand
Easy to understand